Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00757614
First received: September 22, 2008
Last updated: August 23, 2013
Last verified: April 2010
  Purpose

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer in East Anglia, Trent, or West Midlands of the United Kingdom.


Condition Intervention
Bladder Cancer
Brain and Central Nervous System Tumors
Esophageal Cancer
Intraocular Melanoma
Kidney Cancer
Lymphoma
Melanoma (Skin)
Pancreatic Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Genetic: DNA analysis
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
Other: questionnaire administration

Study Type: Observational
Official Title: A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Acquisition of epidemiological information and biological material [ Designated as safety issue: No ]
  • Identification of novel cancer susceptibility genes [ Designated as safety issue: No ]
  • Estimation of the age and sex-specific risks associated with variants in predisposition genes [ Designated as safety issue: No ]
  • Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors [ Designated as safety issue: No ]

Estimated Enrollment: 14000
Study Start Date: February 2008
Detailed Description:

OBJECTIVES:

  • To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors.
  • Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series.
  • To estimate the age and sex-specific risks associated with variants in predisposition genes.
  • To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors.

OUTLINE: This is a multicenter study.

Patients complete a detailed epidemiological questionnaire that includes information on education, occupation, smoking habits, alcohol consumption, height, weight, reproductive history (age at menarche, age at pregnancies, parity, and age at menopause), oral contraceptive use, hormone replacement therapy use, family history of cancer, and past medical history.

Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.

In addition to the cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, and prostate cancer are recruited for the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-PROSTATE.

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosed with bladder cancer, kidney cancer, esophageal cancer, pancreatic cancer, brain cancer, malignant melanoma, or lymphoma within the past 5 years
  • Identified through the Cancer Research Network OR through the cancer registry serving any of the following geographic regions of the United Kingdom:

    • East Anglia
    • West Midlands
    • Trent

PATIENT CHARACTERISTICS:

  • Identified by the patient's general practitioner as fit to contact for this study
  • No serious mental illness or retardation

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00757614

Locations
United Kingdom
University of Cambridge Cancer Research UK Recruiting
Cambridge, England, United Kingdom, CB1 8RN
Contact: Contact Person    44-122-374-0166    paul.pharoah@srl.cam.ac.uk   
Sponsors and Collaborators
Cancer Research UK
Investigators
Study Chair: Paul Pharoah, MD Cancer Research UK
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00757614     History of Changes
Other Study ID Numbers: CDR0000598879, MREC-SEARCH-CANCER, MREC-07/MRE05/17
Study First Received: September 22, 2008
Last Updated: August 23, 2013
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
AIDS-related lymphoma
cutaneous lymphoma
adult Hodgkin lymphoma
adult non-Hodgkin lymphoma
intraocular lymphoma
adult T-cell leukemia/lymphoma
primary central nervous system non-Hodgkin lymphoma
primary central nervous system Hodgkin lymphoma
noncutaneous extranodal lymphoma
adult astrocytic tumors
adult brain stem glioma
adult choroid plexus tumor
adult craniopharyngioma
adult embryonal tumor
adult ependymal tumors
adult meningeal tumor
adult oligodendroglial tumors
adult pineal parenchymal tumor
adult brain tumor
intraocular melanoma
bladder cancer
clear cell sarcoma of the kidney
congenital mesoblastic nephroma
esophageal cancer
melanoma
pancreatic cancer
peripheral primitive neuroectodermal tumor of the kidney
renal cell carcinoma
rhabdoid tumor of the kidney
transitional cell cancer of the renal pelvis and ureter

Additional relevant MeSH terms:
Ureteral Neoplasms
Urinary Bladder Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Esophageal Neoplasms
Lymphoma
Melanoma
Nervous System Neoplasms
Pancreatic Neoplasms
Central Nervous System Neoplasms
Uveal Neoplasms
Carcinoma, Transitional Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Lymphoproliferative Disorders

ClinicalTrials.gov processed this record on April 21, 2014